Join the Ophthalmic Surgery group to help and get support from people like you.
Ophthalmic Surgery News
First-Ever Face Transplant That Includes New Eye For Man Maimed by Shock
THURSDAY, Nov. 9, 2023 – An Arkansas man maimed by a massive electrical shock to his face has successfully received the world's first whole-eye and partial face transplant. In a 21-hour surgery...
Man Maimed by Electric Shock Receives First-Ever Face Transplant That Includes New Eye
KEY TAKEAWAYS: An Arkansas man has received the world’s first whole-eye transplant, along with a partial face transplant The man suffered horrific injuries in 2021 when his face touched a live w...
AI Model Can Respond Appropriately to Ophthalmology Questions
FRIDAY, Aug. 25, 2023 – Large language models (LLMs) like ChatGPT can respond to patient-written ophthalmology questions and usually generate appropriate responses, according to a study published...
FDA Approves Iheezo (chloroprocaine hydrochloride ophthalmic gel) for Ocular Surface Anesthesia
Iheezo Represents the First Approved Use in the U.S. Ophthalmic Market of Chloroprocaine Hydrochloride and the First Branded Ocular Anesthetic Approved for the U.S. Ophthalmic Market in Nearly 14...
FDA Medwatch Alert: Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events After Receiving Eye Injections
ISSUE: At least 43 patients reported adverse events after receiving eye injections of Guardian’s Pharmacy Services compounded triamcinolone-moxifloxacin product during cataract surgery. The patients ...
Omeros Corporation Announces FDA Approval of Omidria for Use in Pediatric Patients
SEATTLE--(BUSINESS WIRE)--Dec. 12, 2017-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and...
FDA Medwatch Alert: Compounded Triamicinolone and Moxifloxacin Product for Intravitreal Injection by Guardian Pharmacy Services: Alert to Health Professionals - Serious Adverse Events Reported
[Posted 07/28/2017] ISSUE: FDA received adverse event reports on April 5 and June 1, 2017, concerning at least 43 patients who were administered intravitreal (eye) injections of a drug containing...
FDA Approves Omidria for Use in Cataract and Other Intraocular Lens Replacement Procedures
SEATTLE, June 2, 2014 /PRNewswire/ – Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved Omidria (phenylephrine and ketorolac injection)...
FDA Medwatch Alert: Mobius brand Mitosol (mitomycin for solution) Kit for Ophthalmic Use: Recall-May Not be Sterile
ISSUE: Mobius Therapeutics announced that it is conducting a voluntary recall of 2 lots of Mitosol (mitomycin for solution), 0.2 mg/vial, Kit for Ophthalmic Use. The company cannot exclude the ...
FDA Medwatch Alert: Brilliant Blue G: Recall of Unapproved Drug - Ongoing Investigation of Fungal Endophthalmitis Cases
ISSUE: FDA has received reports of fungal endophthalmitis (eye infections) in patients who were given Brilliant Blue G (BBG) during eye surgeries. Clinicians in several states reported the adverse ...
Mobius Therapeutics Receives Final FDA Approval for New Glaucoma Drug Mitosol
ST. LOUIS, Feb. 9, 2012 /PRNewswire/ – Mobius Therapeutics, LLC, a St. Louis-based ophthalmic company, has received final approval from the U.S. Food and Drug Administration for the platform...
Ask a question
To post your own question to this support group, sign in or create an account.